Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change
31/07/26	€0.5740	+3.61%
30/07/26	€0.5540	-16.57%

Delayed Quote Börse Stuttgart

More quotes

Income Statement and Estimates

More financial data

Delayed Börse Stuttgart Other stock markets 20:33:42 31/07/2026 +03			5-day change	1st Jan Change
0.5740 ^EUR	+3.61%		0.00%	-21.33%

11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	2.88M 3.31M 2.68M 2.46M 4.64M 316M 4.71M 31.56M 12.38M 157M 12.43M 12.15M 527M	P/E 2023	3.28x	P/E 2024	-86x
Enterprise Value	3.96M 4.55M 3.68M 3.38M 6.39M 435M 6.48M 43.41M 17.04M 216M 17.1M 16.72M 725M	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	99.21%	Yield 2023 *	-	Yield 2024	-

11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
16/10/24	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/04/24	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/03/24	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
07/11/23	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
27/10/23	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/04/23	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/03/23	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
23/12/22	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
14/12/22	Twitter to shut down newsletter product Revue next year	RE
06/12/22	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT
05/10/22	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	CI

03-03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
02-25	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
12-10	Klarsen : ALKLA-Attribution gratuite de BSA	PU
12-09	Klarsen : ALKLA-ACTIVITE 3T2025	PU
11-27	Klarsen : ALKLA-Résultat augmentation de capital	PU

Klarsen Stock Börse Stuttgart

Stocks

4YA

FR0011038348

IT Services & Consulting

Valuation: Klarsen

Chart: Klarsen

Latest news : Klarsen

Press Releases: Klarsen

News in other languages: Klarsen

Quotes and Performance

Course Extremes

Managers and Directors: Klarsen

Other IT Services & Consulting

Financials

Company Profile

Quotes

Income Statement and Estimates

07-30	Klarsen : ALKLA – Klarsen ouvre une nouvelle séquence et donne rendez-vous à ses actionnaires le 27 août – 30 Juillet 2026
07-30	Klarsen : ALKLA-CP KLARSEN-nouvelle séquence
07-24	Klarsen : ALKLA – Klarsen annonce la résolution amiable de son litige avec la société PADAM – 24 Juillet 2026
07-24	Klarsen : ALKLA-Résolution litige PADAM à l'amiable
07-22	KLARSEN : Rapport Financier Annuel 2025

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	01/07/2008
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	01/01/2013

Director	Title	Age	Since
Patrice Coffe BRD	Director/Board Member	57	14/06/2010
Gérard Parrou BRD	Director/Board Member	74	27/06/2014
Frédéric Bartoli BRD	Director/Board Member	-	23/03/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	+3.61%	0.00%	-31.94%	-83.01%	2.4M
IBM	-0.62%	+3.14%	-12.74%	+53.22%	209B
ACCENTURE PLC	+1.31%	+12.99%	-37.82%	-47.50%	99.92B
SNOWFLAKE INC.	+0.23%	+11.61%	+33.86%	+68.36%	103B
TATA CONSULTANCY SERVICES LTD.	-2.72%	+5.47%	-22.53%	-29.50%	92.16B
RELX PLC	-2.54%	+1.52%	-33.77%	-0.50%	62.81B
INFOSYS LIMITED	-2.16%	+7.90%	-25.60%	-15.70%	49B
FUJITSU LIMITED	-6.23%	+12.79%	+9.88%	+102.21%	42.45B
HCL TECHNOLOGIES LIMITED	-0.43%	+8.21%	-8.78%	+22.05%	38.34B
NEC CORPORATION	-5.24%	+11.79%	+9.22%	+248.32%	41.61B
Average	-2.02%	+11.23%	-12.02%	+31.80%	82.06B
Weighted average by Cap.	-1.31%	+11.09%	-10.73%	+34.44%

	2023	2024
Net sales	5.03M 5.78M 4.68M 4.3M 8.11M 552M 8.24M 55.14M 21.64M 275M 21.71M 21.24M 921M	6.31M 7.26M 5.87M 5.39M 10.18M 693M 10.34M 69.24M 27.18M 345M 27.27M 26.67M 1.16B
Net income	2.75M 3.16M 2.56M 2.35M 4.44M 302M 4.51M 30.18M 11.85M 150M 11.88M 11.62M 504M	-47.76K -54.95K -44.46K -40.82K -77.08K -5.25M -78.28K -524K -206K -2.61M -206K -202K -8.76M
Net Debt	-634K -730K -591K -542K -1.02M -69.67M -1.04M -6.96M -2.73M -34.69M -2.74M -2.68M -116M	1.08M 1.24M 1.01M 924K 1.74M 119M 1.77M 11.86M 4.65M 59.08M 4.67M 4.57M 198M

3 months	+93.03%
6 months	-37.89%
Current year	-34.36%

3 years	0.21		3.81
5 years	0.21		3.86